Loading
NASDAQHealthcareBiotechnology
Latest quote
$3.79
−$0.04 · -1.04%
Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.
Latest quote
$3.79
−$0.04 · -1.04%
After-hours
$3.79
$0.00 · 0.00%
Sep 10, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.
Day range
Current $3.79
52-week range
Current $3.79
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
35
Expensive
Sentiment
43
Mixed
Risk
70
High Risk
Momentum
33
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.
Day range
Current $3.79
52-week range
Current $3.79
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 362K USD | — | 341K USD | — | — |
| Gross profit | −362K USD | — | −341K USD | — | — |
| Research and development | 42.63M USD | 31.7M USD | 24.79M USD | 16.81M USD | 21.09M USD |
| Selling, general, and administrative | 21.92M USD | 17.45M USD | 18.62M USD | 20.74M USD | 26.4M USD |
| Operating expenses | 64.19M USD | 49.15M USD | 43.27M USD | 67.06M USD | 47.49M USD |
| Interest income | 6.33M USD | 4.14M USD | 2.73M USD | 1.11M USD | 237K USD |
| Interest expense | — | — | — | 1.14M USD | 1.74M USD |
| Depreciation and amortization | 362K USD | 332K USD | 341K USD | 248K USD | 117K USD |
| Operating income | −64.55M USD | −49.15M USD | −43.61M USD | −67.06M USD | −47.49M USD |
| Net income | −57.44M USD | −44.6M USD | −40.42M USD | −65.95M USD | −47.25M USD |
Company facts updated Sep 11, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$12.00
216.62% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jan 10, 2020 | 1:40 | — | — |
Effective Jan 10, 2020
1:40
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI6.5M0.00%2.3T USD0.03%$373.24-0.62%
iShares Russell 2000 ETFIWM5.1M0.01%80.51B USD0.19%$287.7-1.01%
Vanguard Extended Market ETFVXF2.3M0.00%93.7B USD0.05%$236.16-1.05%
iShares Russell 2000 Value ETFIWN1.81M0.01%14.61B USD0.24%$218.97-0.68%
Vanguard Russell 2000 ETFVTWO1.15M0.01%17.4B USD0.06%$116.34-1.00%
iShares Micro-Cap ETFIWC689.19K0.05%1.49B USD0.60%$190.1-1.22%
U.S. Micro Cap Portfolio ETFDFMC581.18K0.01%7.73B USD0.43%$58.7359-0.78%
Vanguard U.S. Momentum Factor ETFVFMO542.36K0.03%1.8B USD0.13%$226.59-1.42%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCU.S. Micro Cap Portfolio ETFDFMCVanguard U.S. Momentum Factor ETFVFMOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
